EJC Skin Cancer
Publisher: Elsevier · ISSN 2772-6118 · 85 articles
- A-455 - Antibiotic and corticosteroid exposure shapes the gene expression landscape of metastatic melanoma
- A-139 - Application of the Integrated Model of Behavior to Preventive Health Campaigns in the Setting of Melanoma
- A-214 - Autophagy as a therapeutic target in BRAFV600E melanoma cells through ULK-1 and Vps34 inhibition
- A-342 - BLUEBONNET: Phase II Study of Nivolumab in combination with Relatlimab in Patients with Active Melanoma Brain Metastases
- A-397 - Circulating immune cell profiles associated with immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors
- A-274 - Concordance between circulating tumor DNA and tissue DNA genotyping in patients with advanced melanoma: SCRUM-Japan MONSTAR-SCREEN-1 study
- A-478 - Different metallothionein-isoforms as a potential marker of melanoma metastasis
- A-472 - Expert-Informed Melanoma Classification with Dermoscopic and Histopathological Data: Incorporating Diagnostic Uncertainty for Real-World Clinical Deployment
- A-194 - Investigation of Cellular Mechanism through which Salmonella Enterica Serovar Enteritidis Induces Melanoma Cell Death
- A-448 - Melatonin elevates responses to targeted therapy for human melanoma
- A-414 - MicroRNA-Driven Regulatory Networks in Melanoma Progression: Insights from Transcriptomic and Functional Analyses
- A-586 - Modelling melanoma using large-scale, heterogeneous and incomplete multi-omic datasets
- A-417 - Organ-Specific Metastasis of Malignant Melanoma: The Role of Integrin-Mediated Endothelial Adhesion
- A-646 - Ph I/IIa dose finding study of Triplet regimen of Relatlimab (RELA) Ipilimumab (IPI) and NIvolumab (NIVO) in first line TherapY of metastatic melanoma (MM) (TRINITY)
- A-175 - Phase I dose escalation and expansion study of PRAME T-cell receptor (TCR) engineered IL15-transduced cord blood–derived natural killer (NK) cells in patients with recurrent and/or refractory melanoma (PRAMETIME-Mel)
- A-475 - Proteomic profiling identifies response-associated pathways in immunotherapy-treated melanoma
- A-660 - Spatial Characterisation of the Tumour Microenvironment in Early-Stage Melanoma Offers Improved Prognostic Outcome Prediction
- A-386 - Spatial transcriptomics reveals coordinated rewiring of immune-stromal niches toward a suppressive microenvironment in metastatic vs primary human melanoma
- A-211 - Toward Safe Discontinuation of Immunotherapy in Melanoma: A Multimodal Predictive Model for Relapse Risk
- A-641 - Trends in Melanoma Incidence and Prevalence in Greece, 2019–2024: A Nationwide Real-World Study
- A-388 - Cancer-associated fibroblasts switch from immune-activating towards immune-suppressive function during cutaneous squamous cell carcinoma disease progression
- A-532 - Circulating CD39+ regulatory T cells (Tregs) as a predictive biomarker cutaneous squamous cell carcinoma (CSCC)of anti-PD-1 resistance in advanced
- A-254 - Development and Preliminary Evaluation of Postbiotic-Based Chitosan and Carbopol Spray Formulations for Supportive Skin Care in Oncology-Associated Cutaneous Complications
- A-422 - Dissecting the shift in YAP/TAZ signalling modalities with disease progression in cancer-associated fibroblasts of cutaneous squamous cell carcinoma
- A-213 - Efficacy and safety of tirbanibulin 1% ointment in elderly patients with actinic keratosis: a pooled analysis of Phase 3 clinical trials
- A-358 - Efficacy, safety and willingness to be retreated with tirbanibulin 1% ointment in patients with actinic keratosis over a field treatment up to 100 cm²
- A-355 - Gene Signatures as Predictive Biomarkers for PD-1 Blockade in Cutaneous Squamous Cell Carcinoma
- A-241 - Genomic Profiling to Predict Immunotherapy Response in Merkel Cell Carcinoma
- A-140 - IFN-γ-Loaded Dissolvable Sugar Microneedles for Local Intradermal Delivery in Cutaneous Squamous Cell Carcinoma
- A-141 - Imiquimod-Loaded Dissolving Microneedles for Enhanced Dermal Penetration in Basal Cell Carcinoma Immunotherapy: A Feasibility and Delivery Study